Sonnet BioTherapeutics Holdings EBIT

Sonnet BioTherapeutics Holdings (SONN) currently reports a EBIT of $-16M as of September 2025. That compares with $-12M in the prior-year period — down 34.0% year over year. That is below the Consumer Staples sector average of $21B. Use the charts on this page to explore Sonnet BioTherapeutics Holdings's EBIT history and peer comparisons.

Sonnet BioTherapeutics Holdings's EBIT decreased from $-12M to $-16M — a 34.0% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sonnet BioTherapeutics Holdings's EBIT of $-16M is lower than the Consumer Staples sector average of $21B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Sonnet BioTherapeutics Holdings reported $-16M in EBIT as of September 2025. That compares with $-12M in the prior-year period — down 34.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-16M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Staples average is $21B. From there, open related valuation or income-statement pages for Sonnet BioTherapeutics Holdings, and consider following SONN for alerts when major investors trade the stock.